Your Patients Wait Months Between-Visits. Their Disease Does Not.
A flare in week six of a twelve-week interval is managed by the patient, alone, on whatever they remember from the last appointment. A lapsed methotrexate lab goes unnoticed until someone checks. A biologic authorization expires and the patient simply stops the drug.
Rheumatology has one of the longest visit intervals in medicine and one of the heaviest between-visit management burdens. That combination is the case for the program.
The Opportunity
This Is a Care Management Specialty, Not a Device Specialty
We will be direct, because the alternative is selling you something that will not work. Remote physiologic monitoring has limited application in rheumatology. There is no daily measurement in rheumatoid arthritis equivalent to a weight in heart failure, and a device program here would be an exercise in generating readings nobody acts on.
What rheumatology has instead is an unusually heavy load of exactly the work chronic care management was designed for: medication safety monitoring, laboratory surveillance, access logistics, infection risk management and flare triage. That work is substantial; it is unfunded in most practices, and it is where the value sits.
Who Qualifies
Which of Your Patients Qualify
The populations where between-visit management most affects outcomes:
Rheumatoid arthritis on DMARD or biologic therapy:
The core population, where laboratory monitoring obligations and infection risk are continuous.
Systemic lupus erythematosus:
Multi organ involvement, frequent comorbidity, and a flare pattern that rewards early detection.
Psoriatic arthritis and axial spondyloarthritis on advanced therapy:
Where access logistics and adherence drive outcomes as much as agent selection does.
Vasculitis and other conditions on prolonged steroid therapy:
The population carrying the heaviest surveillance obligations attached to treatment.
Polymyalgia rheumatica during steroid taper:
Tapers are where symptoms recur and patients self-adjust without telling anyone.
Patients on methotrexate:
Ongoing laboratory monitoring is a safety requirement and a recurring adherence failure.
Rheumatologic disease with cardiovascular or metabolic comorbidity:
Inflammatory disease carries elevated cardiovascular risk that is routinely under-managed.
And who we would leave out:
Stable osteoarthritis with no systemic therapy and no second qualifying condition.
Patients in sustained remission off therapy with no monitoring obligations.
Patients already enrolled in a care management program elsewhere.
Program Fit
Where Each Program Does the Work
CCM is the entire program here
The recurring work in rheumatology is safety monitoring and logistics. Immunosuppressive therapy carries laboratory obligations that have to be met on schedule. Biologics require authorization, specialty pharmacy coordination and infusion scheduling. Steroid exposure brings its own surveillance requirements. Every patient on immunosuppression needs infection vigilance and vaccination timing that works around their therapy.
Each of those is a discrete, protocol-driven task with a deadline. Collectively they consume a great deal of clinical staff time, and they are the first things to slip when a practice is busy.
RPM has a narrow and honest role
Blood pressure monitoring has a legitimate place for patients on long-term steroids or agents with hypertensive effects, and for those with cardiovascular comorbidity, which is a substantial share of an inflammatory disease panel.
Beyond that we do not recommend a device program in rheumatology. Patient reported outcome tracking, meaning disease activity scores and function measures, is clinically valuable and sits under the remote therapeutic monitoring code family rather than physiologic monitoring. If that interests you it is a separate conversation with different requirements, and we would rather have it properly than fold it into an RPM pitch.
Monthly Touchpoint
What the Monthly Touchpoint Actually Covers
Rheumatology monthly contact is dominated by safety and logistics:
Laboratory monitoring compliance.
Whether required labs were drawn on schedule, results reviewed against your parameters, and the next draw booked. The highest-value item on the call for any patient on methotrexate or a similar agent.
Infection surveillance.
Recent illness, fever, planned dental or surgical procedures, exposure history. Immunosuppressed patients need asking directly and regularly, because they frequently do not think to report.
Steroid exposure management.
Current dose, taper adherence, and the surveillance that chronic exposure obliges across glucose, bone health, blood pressure and ophthalmic screening.
Access and supply continuity.
Authorization status, specialty pharmacy delivery, infusion appointments, copay assistance. Interruptions here are among the most common reasons patients come off effective therapy.
Flare assessment and triage.
Structured questions about disease activity between visits, with escalation criteria you define, so a patient in a genuine flare reaches you rather than waiting out the interval.
Vaccination timing.
Live vaccine contraindications, timing around biologic dosing, and keeping routine immunization current in a population where it matters more and is tracked less.
Clinical value
What Changes
The most common concrete outcome is unremarkable and entirely protective. A coordinator identifies that a patient on methotrexate has gone longer without laboratory monitoring than the protocol allows, and the draw happens before a problem develops rather than after one is discovered.
The second is continuity of therapy. A meaningful share of patients who appear to fail a biologic have simply stopped taking it. An authorization lapsed, a specialty pharmacy shipment did not arrive, a copay became unaffordable and nobody was told. Catching those interruptions is often the difference between staying on an effective drug and being switched to a second-line agent for a reason that had nothing to do with efficacy.
We will not sell you a device program. If a vendor is proposing remote physiologic monitoring across a rheumatology panel, ask what is being measured daily and what clinical decision the measurement drives. In most rheumatologic disease there is no good answer. The value in this specialty is care management, the case for it is strong, and it does not need a device attached to be worth doing.
Questions Rheumatology Practices Ask
Our patients have a close relationship with us. Does a coordinator disrupt that?
The coordinator handles logistics and surveillance: labs, authorizations, supply, scheduling and structured safety questions. Clinical judgment and the therapeutic relationship stay with you. Most rheumatology patients experience it as the practice becoming easier to deal with, because someone is finally chasing the administrative work that used to be theirs to chase.
Can a coordinator assess disease activity?
They can collect structured patient reported information against a protocol you approve, including pain, morning stiffness duration, joint counts where the patient can report them and functional measures, and escalate anything meeting your criteria. They do not interpret it or make treatment decisions.
We already have staff chasing prior authorizations. Is this duplicative?
It can be. If your authorization process is working well, we would rather build the program around laboratory monitoring and flare triage than duplicate something already handled. Our services stack can take on authorization work separately if that is the actual pressure point. We would rather scope it accurately than sell you both.
How does this interact with infusion scheduling?
Coordinators track infusion appointments, confirm attendance, follow up on missed doses and coordinate pre-infusion laboratory requirements. Missed infusions usually reflect logistics rather than patient choice, which makes them recoverable when somebody notices promptly.
Start With Your Methotrexate and Biologic Patients
They carry the heaviest monitoring obligations and the clearest safety case, which makes them the cohort where a structured program proves itself fastest.